TEDU
Teduglutide
A 33-amino-acid analogue of glucagon-like peptide-2 in which the alanine at position 2 is replaced by glycine. That single substitution is the whole design: position 2 is where dipeptidyl peptidase-4 cleaves the native peptide. It binds the GLP-2 receptor, a relative of the GLP-1 receptor with a separate distribution.
Teduglutide has 41 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 1,383 planned or enrolled participants across the 36 studies that published a figure. An FDA-approved product contains Teduglutide — GATTEX KIT (NDA203441). 270 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Teduglutide; the registry search is fuzzy, so every match is re-checked. None of this says whether Teduglutide works or is safe.
FDA status
Approved
Human studies
41
Furthest phase
Phase 4
Papers, 10 yr
270
Readership
556
monthly average, Feb–Jul 2026
Tracking since 2026-08-02 · About this data
What has actually been tested in humans
An approved product exists
41
Registered human studies
Phase 4
Furthest phase reached
1,383
Planned or enrolled participants, across 36 studies that published a figure
Approved
FDA-approved product — GATTEX KIT
50 loose registry matches were checked and 41 confirmed — 9 named something else and were discarded. We count a study only when Teduglutide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Teduglutide is, and what it has been studied for
Teduglutide is classified by ChEMBL as a protein, and appears in trial registrations under ALX 0600 and ALX-0600. Its FDA substance identifier is 7M19191IKG.
Across 41 registered trials, it has been studied in Short Bowel Syndrome, Hyperlipidemias, Crohn's Disease and Healthy Volunteers. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Shire and Takeda among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Teduglutide reached Phase 4 across 41 registered trials.
An FDA-approved product contains Teduglutide. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Teduglutide?
Papers published each year that name Teduglutide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 21 | 4 | Yes |
| 2018 | 22 | 5 | Yes |
| 2019 | 28 | 3 | Yes |
| 2020 | 41 | 2 | Yes |
| 2021 | 31 | 3 | Yes |
| 2022 | 28 | 2 | Yes |
| 2023 | 35 | 0 | Yes |
| 2024 | 39 | 1 | Yes |
| 2025 | 41 | 1 | Yes |
| 2026 | 31 | 1 | No |
270 papers and 22 registered trials between 2017 and 2026. A paper counts when “Teduglutide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Teduglutide
270 indexed papers name Teduglutide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Teduglutide
- Definition, classification, and causes of short bowel syndrome
- Understanding short bowel syndrome: Current status and future perspectives
- Updates in Intestinal Failure Management
- European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN: Part 2: Screening, Special Populations, Nutritional Goals, Supportive Care, Primary Care Perspective
- Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support
- Teriflunomide
- Teduglutide in Crohn's disease
Collected 2026-08-02from PubMed, phrase-matched on “Teduglutide” in title and abstract. Run the same search.
About Teduglutide
A 33-amino-acid analogue of glucagon-like peptide-2 in which the alanine at position 2 is replaced by glycine. That single substitution is the whole design: position 2 is where dipeptidyl peptidase-4 cleaves the native peptide. It binds the GLP-2 receptor, a relative of the GLP-1 receptor with a separate distribution.
- Also known as
- ALX-0600
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.